



QVAR[®] (beclomethasone dipropionate HFA) – Revised indication

- On September 29, 2017, the [FDA approved](#) a revision to the indication for [QVAR \(beclomethasone dipropionate HFA\)](#). Information regarding asthma patients requiring oral corticosteroid therapy was removed.
 - Previously, QVAR was also indicated for asthma patients requiring oral corticosteroid therapy, where adding QVAR may reduce or eliminate the need for oral corticosteroids.
- QVAR is now only indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 5 years of age and older.
 - QVAR is not indicated for the relief of acute bronchospasm.
- The dosing section was also revised to state that dosing is based on previous asthma therapy and disease severity.
 - Dosing information for patients receiving chronic oral corticosteroid therapy was removed.
- Previously, similar updates were made to the [Aerospan[®] \(flunisolide\)](#) and [Flovent[®] HFA \(fluticasone propionate\)](#) drug labels.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.